Sanjay Rakhade MD, PhD

Sanjay Rakhade MD, PhD is a physician-scientist and currently serves as Senior Medical Director, at Sarepta Therapeutics. Sanjay is a neurologist by training, and oversees the clinical trials for exon-skipping therapies in clinical development for DMD at Sarepta Therapeutics. He was previously at Sanofi Genzyme, where he had roles of increasing responsibility over a period of 6 years, most recently as Global Medical Lead, Multiple Sclerosis and Neurology.
Sanjay has experience across multiple phases of clinical development, and across a spectrum of therapies and disorders, including pivotal Phase 3 studies for alemtuzumab (Lemtrada) for multiple sclerosis, and eliglustat tartrate (Cerdelga) for Gaucher disease. In addition, Sanjay has worked on multiple Phase 1 and 2 programs in MS, and enzyme replacement therapies in lysosomal storage diseases. Sanjay has published his research in several leading neurology journals including Nature Reviews Neurology, Annals of Neurology, and Journal of Neuroscience etc.
Prior to Sanofi Genzyme, Sanjay was on faculty at the Department of Neurology Harvard Medical School and Children’s Hospital, Boston. Sanjay received his MD from Grant Medical College, University of Bombay, his PhD in Molecular Medicine and Genetics from Wayne State University School of Medicine, and medical training in neurology at Children’s Hospital of Michigan and Detroit Medical Center. He also did a fellowship in pediatric neurology at Children’s Hospital, Boston and Harvard Medical School.